Clinical Trials Logo

Clinical Trial Summary

This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, cells in the blood and cells in the skin that cause allergies. The investigators will compare the changes in the nose to changes in the skin and blood cells.

Objective: To test the hypothesis that treatment with omalizumab will decrease the nasal allergen challenge late-phase eosinophil count in nasal brushings at the time when blood basophils have become hypo-responsive to in vitro allergen exposure.


Clinical Trial Description

This is a randomized, placebo-controlled, double-blind, parallel group design study that includes 3.5 months of treatment with omalizumab or placebo and a 3 month follow-up. All subjects will be cat allergic.

Twenty four subjects (1:1 randomization) will undergo a cat allergen nasal challenge prior to treatment and another challenge after 2 months of treatment or when their blood basophils become hyporesponsive to cat allergen in vitro. A second group of 10 subjects (1:1 active:placebo), will not undergo nasal challenges. This group will participate in an ancillary study in which the effects of omalizumab on gene expression profiles in peripheral blood cells will be studied. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01003301
Study type Interventional
Source Johns Hopkins University
Contact
Status Completed
Phase Phase 2
Start date October 2009
Completion date September 2013

See also
  Status Clinical Trial Phase
Terminated NCT02959073 - Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients N/A
Completed NCT00987909 - Exposure Chamber Trial With Cat Immunotherapy Phase 2
Completed NCT01383590 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis Phase 1
Completed NCT01383603 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis Phase 1
Completed NCT02311413 - A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy Phase 2
Completed NCT02237196 - Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy Phase 1/Phase 2
Completed NCT02399579 - Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients N/A
Terminated NCT01292070 - Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy Phase 0
Completed NCT00867906 - Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma Phase 2
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01033344 - Cat-PAD Exposure Chamber Study Phase 2
Completed NCT00685711 - Safety of Cat-PAD in Cat Allergic Subjects Phase 1/Phase 2
Completed NCT02040844 - Phase III Cat-PAD Follow-on Study Phase 3
Completed NCT01604018 - An Optional Two Year Follow Up Study to Study CP005A N/A
Completed NCT01272323 - Cat-PAD Follow on Study N/A
Completed NCT03838731 - Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge Phase 2
Completed NCT00729508 - Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects Phase 2
Recruiting NCT05331170 - Viral Mucosal Reprogramming Phase 2